Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment
Pasi A. Jänne(Harvard University), Melissa L. Johnson(Tennessee Oncology), Lei Bao(Revolution Medicines (United States)), Valentina Boni, Benjamin Herzberg(Columbia University), Kyriakos P. Papadopoulos(Texas Oncology), Mariano Ponz‐Sarvisé(Cold Spring Harbor Laboratory), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Yoon Ji Choi(Korea University Medical Center), Luxi Yang(Memorial Sloan Kettering Cancer Center), Pei Jye Voon(University Health Network), Richa Dua(Revolution Medicines (United States)), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Stéphanie Bordenave-Juchereau(La Rochelle Université), David Sommerhalder(Texas Oncology), Michelle Yang(Revolution Medicines (United States)), Ewa Kalinka‐Warzocha(Apple (Israel)), Rakesh Raman(Kent and Canterbury Hospital), Frédéric Bigot(Institut de Cancérologie de l'Ouest), Bruna Pellini(University of South Florida), Jonathan W. Riess(University of California Davis Medical Center), Lauriane Eberst(Institut de Cancérologie Strasbourg), Hyun Woo Lee(Yonsei University), Sofia Wong(Revolution Medicines (United States)), Sai I. Ou(University of California, Irvine), J. Thaddeus Beck(Highlands Oncology Group), Yunming Mu(Revolution Medicines (United States)), Loïc Lebellec(Centre Oscar Lambret)
Cited by 60
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k